Asset Details
Do you wish to reserve the book?
Effectiveness of a Prostacyclin IP Receptor Agonist in Patients With Pulmonary Arterial Hypertension in the Real-world Andalusian Setting: The RAMPHA Study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effectiveness of a Prostacyclin IP Receptor Agonist in Patients With Pulmonary Arterial Hypertension in the Real-world Andalusian Setting: The RAMPHA Study
Do you wish to request the book?
Effectiveness of a Prostacyclin IP Receptor Agonist in Patients With Pulmonary Arterial Hypertension in the Real-world Andalusian Setting: The RAMPHA Study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effectiveness of a Prostacyclin IP Receptor Agonist in Patients With Pulmonary Arterial Hypertension in the Real-world Andalusian Setting: The RAMPHA Study
2024
Overview
The pillar for therapeutic decisions in the evolution of pulmonary arterial hypertension (PAH) is the patients’ prognostic stratification.
A retrospective cohort study was conducted in a Spanish real-world setting to assess the clinical improvement of PAH patients treated with selexipag measured as changes in the risk profile. Secondary objectives were to describe their baseline characteristics, initial risk status, and variables used to assess patient survival and adverse events.
Total 42 patients (mean age 52.36 [SD: 15.09] years) were included. All had received initial endothelin receptor antagonist treatment and 95.2% dual therapy with phosphodiesterase-5 inhibitor or riociguat. At 6 to 12 months from baseline, patients risk stratification tripled the percentage of patients with low risk, and a trend towards improved risk stratification (P = 0.122). World Health Organization functional class changed, with more patients in milder classes (P = 0.003), and symptom progression slowed down (P < 0.0001). At 3-years, survival was 85.7% and the estimated median survival time was 2.73 years (SD: 1.351; 95% CI: 2.51–2.95).
Selexipag did not achieve a significant improvement in risk profile, although it did show an excellent survival rate, effectively improved functional class, and delayed symptom progression in real life. Selexipag was well tolerated and showed a favorable safety profile, supporting a clinical benefit for PAH patients.
Publisher
Elsevier Inc,Elsevier Limited
Subject
/ Acetamides - therapeutic use
/ Adult
/ Aged
/ Agonists
/ Antihypertensive Agents - adverse effects
/ Antihypertensive Agents - therapeutic use
/ Endothelin Receptor Antagonists - adverse effects
/ Endothelin Receptor Antagonists - therapeutic use
/ Female
/ Humans
/ Hypertension, Pulmonary - drug therapy
/ Hypertension, Pulmonary - physiopathology
/ Male
/ Patients
/ Peptides
/ Phosphodiesterase 5 Inhibitors - adverse effects
/ Phosphodiesterase 5 Inhibitors - therapeutic use
/ Pulmonary arterial hypertension
/ Pulmonary Arterial Hypertension - drug therapy
/ Pulmonary Arterial Hypertension - physiopathology
/ Pyrimidines - adverse effects
/ Pyrimidines - therapeutic use
/ Receptors, Epoprostenol - agonists
/ Spain
/ Survival
